The tools applied by the research group include organic and inorganic synthesis, physical-organic methodologies, advanced spectroscopy, and electrochemistry, as well as biochemical protocols. Our 1999 discovery on the synthesis of what remains the most stable and accessible corrole to date created an enormous flurry of research activity on corrole-chelated metal complexes. This is reflected in the transition from what used to be no more than a scientific curiosity to a highly vibrant field. As of 2017, 150 out of the 180 publications that we have published are on corroles and we hold 7 patents on these molecules and their utility.
On top of fundamental research, we are promoting practical aspects in the fields of asymmetric catalysis, alternative energy, and drug development.
· Coordination chemistry: stability of high-valent & reactivity of low-valent corrole-chelated metal complexes; controlling photophysical and chemical properties of metallocorroles. Fig1
· Catalysis: Development/improvement of new/known catalytic processes with emphasis on full characterization of the catalytic cycle and the various reaction intermediates. Fig2
· Energy: Recent focus is on alternative energy and fuel cells, which includes the development of new chromophores for dye sensitized solar cells, the design of catalysts for the 4-electron/4-protons reduction of oxygen to water, the hydrogen evolution reaction, and for water oxidation (the oxygen evolution reaction). Another relevant approach is to take advantage of the strong reducing power of metallocorroles for the activation of small molecules/ions like carbon dioxide and halides. Fig3
· Medicine: Group members who are involved in the medicine-oriented projects perform the biochemical and biological investigations by themselves, in collaborations with research groups from the Technion’s medical school. The relevance of chemistry-only results regarding catalytic decomposition of reactive oxygen and nitrogen species are currently demonstrated in atherosclerosis, diabetes, neurodegenerative diseases, and cancer. The last aspect and some novel imaging procedures are also being developed within a large collaboration in South California (Caltech, City of Hope, and Cedars Sinai Medical Center). Fig4
Post doc: Princeton University, Princetion, NJ, USA, 1988-1990 in the field of porphyrin chemistry (under JT Groves)
Ph.D: Bar Ilan University, Ramat Gan, Israel, 1987, in Physical Organic Chemistry
Bar-Ilan interdisciplinary award for excellent M.Sc. candidates, 1981.
Landau prize for excellence (M.Sc. thesis), 1983.
Bar-Ilan scholarship for excellent starting doctoral students, 1984.
Bar-Ilan scholarship for excellence (Ph.D. students), 1985.
Pulver award for excellence (Ph.D. candidates), 1986.
Fulbright postdoctoral fellowship, 1988.
Koebner-Klein award for starting faculty members, 1991.
Henri Gutwirth award for excellence in research, 1995.
Ray and Miriam Klein award for “The development of porphyrin-like catalysts for asymmetric catalysis”, 1999.
Mitchel award for the promotion of inventions with commercial potential, 4/2000.
Hershel Rich – Technion Innovation Award, 5/2000.
Henry Taub Prize for Excellence in Research – 5/2003.
The Reba May & Robert D. Blum Named Professorship (“Kathedra”) – 2/2004.
Schulich Award for Excellence in teaching, 2009.
Hershel & Hilda Rich Innovation Award, 6/2013
Moore Distinguished Scholar, Caltech, 8/2013
Israel Chemical Society Award for the Outstanding Scientist, 2/2014
Xingda Lecture, Peking University, Beijing, 9/2014
Resnick Distinguished Lecture, California Institute of Technology, 9/2017
Mahler Lecture, Univ. of Texas at Austin, 4/2018
JSPS Invitational Fellowship for Research in Japan, 1/2018
Hans Fischer Career Award in Porphyrin Chemistry, 7/2018
|Dr. Atif Mahammedemail@example.com||509||3731|
|Dr. Irena Saltsmanfirstname.lastname@example.org||510||2681|
|Dr. Amir Mizrahiemail@example.com||509||2681|
|Dr. Sudhakar Kolanufirstname.lastname@example.org||510||2681|
|Dr. Woormileela Sinhaemail@example.com||510||2681|
|Dr. Pinkey Yadavfirstname.lastname@example.org||509||3731|